Biocom Institute is a 501(c)(3) organization, classified under Science & Technology (NTEE U99). Contributions are tax-deductible.
10996 Torreyana Rd Ste 200, San Diego, CA 92121-1160
Among the 23 scored science & technology organizations in San Diego, Biocom Institute holds 2.9 months of operating reserves (peer median 10.1 months), runs a typical yearly surplus of 13.2% (peers: deficit of 3.7%), and has cut spending 7.7% a year (peers: grown spending 14.8% a year).
In fiscal year 2024 it reported $1,409,806 in revenue and $1,245,113 in expenses, with contributions making up 99.9% of revenue.
Biocom California institute is a 501(c)(3) Organization established in 2008 by biocom California, the largest and most experienced advocate for California's life science sector. Our mission is to develop and promote a skilled and diverse pipeline of talent to accelerate the growth of California's life science ecosystem.
Largest programs · fiscal year 2024
Novaworks: This agreement establishes a partnership between the city of sunnyvale's nova workforce boardand biocom California institute to deliver life science industry workforce development servicesunder the workforce innovation and opportunity act. The partnership focuses on three keycomponents: (1) Supporting life science companies adjusting their workforce size through workeradjustment and ret… Read more
Novaworks: This agreement establishes a partnership between the city of sunnyvale's nova workforce boardand biocom California institute to deliver life science industry workforce development servicesunder the workforce innovation and opportunity act. The partnership focuses on three keycomponents: (1) Supporting life science companies adjusting their workforce size through workeradjustment and retraining notification (warn) assistance, (2) Facilitating business and job seekerengagement through industry events and webinars, and (3) Implementing a career explorationfellowship program connecting job seekers with mentors and training opportunities. The totalfunding for this partnership is $150,000 for the period from July 31, 2024, through July 30, 2025. Theagreement represents a continuation of workforce development eorts aimed at enhancing novaworkforce services' connections to life science industry employers and improving employmentoutcomes for job seekers.
$17,577 spent · 1.6% of program spending
This agreement establishes a partnership between the verdugo workforce development board(vwdb) and biocom California institute to deliver life science industry workforce developmentservices. The partnership focuses on two key components: (1) Implementing a career explorationfellowship program and (2) Supporting the growth and enhancement of the biocom institutetechnician certification (biotc).the… Read more
This agreement establishes a partnership between the verdugo workforce development board(vwdb) and biocom California institute to deliver life science industry workforce developmentservices. The partnership focuses on two key components: (1) Implementing a career explorationfellowship program and (2) Supporting the growth and enhancement of the biocom institutetechnician certification (biotc).the fellowship program will connect job seekers with mentors and training opportunities throughactivities including program planning, customized marketing materials development, applicationprocessing, mentor-fellow matching, event coordination (orientation, career panels, meet and greetevents), and program monitoring with surveys and check-ins.the biotc program involves collaboration with the vwdb, grifols biologicals LLC, and los angelesvalley college to expand this industry-recognized credential program to support workforcedevelopment in the life sciences sector. This includes technical assistance to enhance thecredential's reach and implementation.the agreement represents a strategic workforce development initiative aimed at strengtheningconnections between job seekers and life science industry employers while developing industryrecognizedcredentials to improve employment outcomes.
$87,664 spent · 8.1% of program spending
This agreement establishes a partnership between the national institute for innovation inmanufacturing biopharmaceuticals (niimbl), santa clara university (scu), biocom californiainstitute, merck sharp & dohme LLC, and genentech to develop and implement the "biocad dataprogramming for biomanufacturing scale-up" project. Running from January 1, 2025 through june30, 2026, the project focuses on four… Read more
This agreement establishes a partnership between the national institute for innovation inmanufacturing biopharmaceuticals (niimbl), santa clara university (scu), biocom californiainstitute, merck sharp & dohme LLC, and genentech to develop and implement the "biocad dataprogramming for biomanufacturing scale-up" project. Running from January 1, 2025 through june30, 2026, the project focuses on four key components:1. Building dissemination channels by implementing biocad with cohorts of industryparticipants including 100 genentech interns, 10 merck employees, 20 biocom student andveteran fellows, and 20+ retraining workers, while launching the biocad intermediate dataprogramming for biomanufacturing certificate nationally.2. Developing primers and intermediate courses in downstream processes analytics includingstatistical methods and biomanufacturing process data programming.3. Creating and evaluating intermediate data programming problems and advanced cases forcomplex end-to-end manufacturing scenarios, with 6-8 hands-on problems and advancedcases focusing on emerging biopharmaceutical manufacturing modalities.4. Adapting biocad materials for community college instructors and retraining programsthrough needs analysis, community college instructor adaptation, and pilotimplementations.additionally, biocom California institute hosts participants of the niimbl experience program, anexclusive all-expenses-paid immersion program that provides first and second-year collegestudents with real-world insight into biopharmaceutical industry careers. The program features afull-day immersive experience at biocom's oice with hands-on activities and direct interactionswith industry professionals. This program aims to increase access to the biopharmaceuticalmanufacturing industry among domestic students, broaden talent pipelines by connecting industrywith talented students, and oer exposure to the entire biopharma manufacturing ecosystem.
$3,241 spent · 0.3% of program spending
Remaining other - amgen, contracosta, lsxp, and lsyl$971,324 spent · 90.0% of program spending
Where each dollar went · fiscal year 2024
Of every dollar it spent, 87¢ went to programs, 13¢ to management and 0¢ to fundraising.
Programs $1,079,806
Management $165,307
Fundraising $0
In the organization's own words to the IRS, shown for context. None of this affects the America's Best Score, and a Form 990 describes programs without measuring their results.
Spending on programs Not scored; America's Best needs 65%+
87%
Meets
Compared with San Diego peers
Measure
This organization
Peer median
Operating reserves
2.9 mo
10.1 mo
Typical margin
+13.2%
−3.7%
Spending growth
−7.7% / yr
+14.8% / yr
Debt load
25.7%
11.9%
Peers: the 23 San Diego science & technology organizations with a score, ranked or below the bar.
Tax filings by year
Financial data extracted from the Form 990 the organization filed with the IRS for each fiscal year. Revenue lines can exceed 100% when other items, such as fundraising event costs, are netted against total revenue.
Revenue$1,409,806Fiscal year 2024
Expenses$1,245,113Fiscal year 2024
Total assets$403,305Fiscal year 2024
Total liabilities$103,585Fiscal year 2024
Fiscal year ending December2024
Revenue$1,409,806
Expenses$1,245,113
Net income$164,693
Net assets$299,720
Notable sources of revenue
Percent of total revenue
Contributions
$1,408,384
99.9%
Program services
$0
0.0%
Investment income
$1,422
0.1%
Other (net)
$0
0.0%
Assets / debt
Total assets
$403,305
Total liabilities
$103,585
Net assets
$299,720
Compensation
Not in our extract for this year.
Fiscal year ending December2023
Revenue$815,255
Expenses$1,091,933
Net income−$276,678
Net assets$135,027
Notable sources of revenue
Percent of total revenue
Contributions
$840,812
103.1%
Program services
$62,952
7.7%
Investment income
$4,250
0.5%
Other (net)
−$92,759
−11.4%
Assets / debt
Total assets
$284,614
Total liabilities
$149,587
Net assets
$135,027
Compensation
Officers and key employees
$189,473
Share of expenses
17.4%
Fiscal year ending December2022
Revenue$1,717,341
Expenses$1,460,934
Net income$256,407
Net assets$373,705
Notable sources of revenue
Percent of total revenue
Contributions
$1,580,619
92.0%
Program services
$209,452
12.2%
Investment income
$722
0.0%
Other (net)
−$73,452
−4.3%
Assets / debt
Total assets
$712,895
Total liabilities
$339,190
Net assets
$373,705
Compensation
Officers and key employees
$149,959
Share of expenses
10.3%
About this data
Figures come from IRS Form 990 filings, through the IRS Exempt Organizations Business Master File (2026-11-09) and e-filed returns. Form 990 data typically lags 12–24 months behind an organization's fiscal year. Found an error?